A Clinical Study to Compare BupiZenge With Lidocaine for Pain Due to Oral Mucositis in Patients With Head and Neck Cancer.

NCT07672236 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

150

Enrollment

INDUSTRY

Sponsor class

Conditions

Head & Neck Cancer
Oral Mucositis

Interventions

DRUG: BupiZenge 25 mg
DRUG: Lidocaine viscous 2%

Sponsor

OncoZenge AB

Collaborators

[object Object]